

Monitoring Report: Respiratory Viruses - August 2024 Data

Samuel Gratzl, PhD

Brianna M Goodwin Cartwright, MS

Patricia J Rodriguez, PhD, MPH

Charlotte Baker, DrPH, MPH, CPH

Duy Do, PhD

Nicholas L Stucky, MD, PhD

Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:

Dr Nicholas Stucky

Truveta, Inc

1745 114th Ave SE, Bellevue, WA 98004

Email: nicholass@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through the last full week of August 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).



Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2019 and August 25, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 642,821 hospitalizations of 592,200 unique patients who tested positive for a respiratory virus between October 01, 2019 and August 25, 2024. Overall, the rate of hospitalizations associated with respiratory viruses remained stable throughout August 2024, with no change compared to July 2024. COVID-associated hospitalizations saw a slight decrease of 2.9%, while influenza-associated hospitalizations dropped significantly by 57.4%. Other respiratory viruses, including HMPV and RSV, reported no hospitalizations during this period, although rhinovirus-associated hospitalizations increased by 61.7%. In the last week of August 2024, respiratory virus-associated hospitalizations accounted for 2.5% of all hospitalizations. For August, test positivity for COVID is high (20.9%) but falling (-5.3%). Test positivity for rhinovirus is high (15.1%) and rising through August (+63.9%). For other viruses, test positivity is relatively low with parainfluenza having the next highest test positivity at 1.4%. No other viruses have a rising test positivity.



Discussion: The data indicates that respiratory virus-associated hospitalizations have stabilized at low levels during August 2024, following a trend of decreasing rates observed earlier in the year. The notable decrease in influenza-associated hospitalizations suggests a continued decline in this virus's impact. In contrast, the increase in rhinovirus-associated hospitalizations highlights its growing significance in the current respiratory virus landscape.

Trends in surveillance

Overall population



	Overall	COVID	Influenza	HMPV	Parainfluenza virus	RSV	Rhinovirus
July 22, 2024	2.5%	2.1%	0.1%	0.0%	0.1%	0.0%	0.3%
August 19, 2024	2.5%	2.1%	0.0%	0.0%	0.0%	0.0%	0.4%
Change (percentage)	-0.0%	-2.9%	-57.4%	-16.0%	-44.0%	-28.0%	+61.7%
Difference (percentage points)	-0.0%	-0.1%	-0.0%	-0.0%	-0.0%	-0.0%	+0.2%





	Overall	COVID	Influenza	HMPV	Parainfluenza virus	RSV	Rhinovirus
July 22, 2024	9.4%	22.1%	0.9%	0.8%	2.0%	0.3%	9.2%
August 19, 2024	9.5%	20.9%	0.7%	0.5%	1.4%	0.2%	15.1%
Change (percentage)	+0.1%	-5.3%	-16.3%	-44.2%	-28.3%	-17.5%	+63.9%
Difference (percentage points)	+0.0%	-1.2%	-0.1%	-0.4%	-0.6%	-0.0%	+5.9%

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



For the overall population, the rate of hospitalizations associated with respiratory viruses remained unchanged in August 2024 compared to July 2024. The slight decrease in COVID-associated hospitalizations (-2.9%) and the significant drop in influenza-associated hospitalizations (-57.4%) counterbalanced the significant increase in rhinovirus-associated hospitalizations (+61.7%). In the last week of August, respiratory virus-associated hospitalizations accounted for 2.5% of all hospitalizations.

For August, test positivity for COVID is high (20.9%) but falling (-5.3%). Test positivity for rhinovirus is high (15.1%) and rising (+63.9%). For other viruses, test positivity is relatively low with parainfluenza having the next highest test positivity at 1.4%. No other viruses have a rising test positivity.

Infants and children (age 0-4)



	Overall	COVID	Influenza	HMPV	Parainfluenza virus	RSV	Rhinovirus
July 22, 2024	1.7%	0.8%	n/a	0.0%	0.1%	0.1%	1.0%
August 19, 2024	2.4%	1.2%	n/a	0.0%	0.1%	0.1%	1.8%
Change (percentage)	+40.6%	+40.2%		+0.2%	-33.2%	+50.2%	+80.9%
Difference (percentage points)	+0.7%	+0.3%		+0.0%	-0.0%	+0.0%	+0.8%




It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

	Overall	COVID	Influenza	HMPV	Parainfluenza virus	RSV	Rhinovirus
July 22, 2024	10.1%	21.0%	1.0%	1.8%	4.8%	1.2%	32.2%
August 19, 2024	10.4%	19.4%	0.9%	1.2%	3.3%	1.2%	42.1%
Change (percentage)	+2.3%	-7.5%	-11.0%	-28.9%	-30.2%	-4.0%	+30.7%
Difference (percentage points)	+0.2%	-1.6%	-0.1%	-0.5%	-1.4%	-0.0%	+9.9%


In the population aged 0-4 years, respiratory virus-associated hospitalizations increased significantly by 40.6% throughout August 2024. This rise was primarily driven by increases in rhinovirus-associated hospitalizations, which rose by 80.9%. In the last week of August, 2.4% of all hospitalizations in this age group were associated with a respiratory virus, with rhinovirus being the largest contributor at 1.8%.

For August, test positivity for COVID is high (19.4%), but peaked in August and is falling (-7.5%). Test positivity for rhinovirus is high (42.1%) and rising (+30.7%). For other viruses, test positivity is lower, with parainfluenza having the next highest test positivity at 3.3%. No other viruses have a rising test positivity.

Older adults (age 65 and over)



	Overall	COVID	Influenza	HMPV	Parainfluenza virus	RSV	Rhinovirus
July 22, 2024	3.6%	3.1%	0.1%	0.0%	0.1%	0.0%	0.2%
August 19, 2024	3.4%	3.1%	0.0%	0.0%	0.1%	0.0%	0.2%
Change (percentage)	-4.7%	-2.0%	-62.9%	-19.4%	-45.8%	-59.7%	+2.5%
Difference (percentage points)	-0.2%	-0.1%	-0.1%	-0.0%	-0.1%	-0.0%	+0.0%



Among older adults (age 65 and over), there was a slight decrease of 4.7% in hospitalizations associated with respiratory viruses in August 2024 compared to July 2024. COVID-associated hospitalizations remained stable, while influenza-associated hospitalizations saw a significant decline of 62.9%. In the last week of August, respiratory virus-associated hospitalizations accounted for 3.4% of all hospitalizations in this age group, with COVID remaining a consistent contributor.

For August, test positivity for COVID is high (21.8%) but falling (-4.1%) compared to the last week of July. Rhinovirus has the next highest test positivity at 4.0%, which has been rising throughout August (+20.6%).

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness, such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death, especially in vulnerable populations such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2019 and August 25, 2024 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions),

medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truvena by constituent health care systems. The data used in this study was provided on September 09, 2024 and included de-identified patient care data primarily located across ten states: California, New York, Florida, Illinois, Ohio, Washington, Arizona, North Carolina, Wisconsin, and Louisiana.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 642,821 hospitalizations of 592,200 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	84,679 (100.00%)	152,638 (100.00%)	154,461 (100.00%)	111,236 (100.00%)	89,186 (100.00%)	592,200 (100.00%)
Age Group						
< 6 months	1,837 (2.17%)	1,507 (0.99%)	2,556 (1.65%)	3,273 (2.94%)	2,334 (2.62%)	11,507 (1.94%)
6 - <12 months	850 (1.00%)	586 (0.38%)	1,152 (0.75%)	1,541 (1.39%)	1,178 (1.32%)	5,307 (0.90%)
1 - <2 years	1,033 (1.22%)	979 (0.64%)	1,692 (1.10%)	2,094 (1.88%)	1,556 (1.74%)	7,354 (1.24%)
2 - 4 years	1,283 (1.52%)	1,043 (0.68%)	2,417 (1.56%)	3,127 (2.81%)	1,955 (2.19%)	9,825 (1.66%)
5 - 17 years	1,430 (1.69%)	1,780 (1.17%)	2,984 (1.93%)	3,470 (3.12%)	2,671 (2.99%)	12,335 (2.08%)
18 - 49 years	17,373 (20.52%)	34,137 (22.36%)	31,549 (20.43%)	15,088 (13.56%)	11,811 (13.24%)	109,958 (18.57%)
50 - 64 years	20,057 (23.69%)	37,944 (24.86%)	31,315 (20.27%)	17,205 (15.47%)	14,352 (16.09%)	120,873 (20.41%)
65 - 74 years	16,489 (19.47%)	31,531 (20.66%)	30,614 (19.82%)	21,489 (19.32%)	17,519 (19.64%)	117,642 (19.87%)
75 - 84 years	14,768 (17.44%)	27,199 (17.82%)	30,338 (19.64%)	25,316 (22.76%)	20,949 (23.49%)	118,570 (20.02%)
85+ years	9,559 (11.29%)	15,932 (10.44%)	19,844 (12.85%)	18,633 (16.75%)	14,861 (16.66%)	78,829 (13.31%)
Sex						
Female	42,176 (49.81%)	74,097 (48.54%)	78,725 (50.97%)	57,961 (52.11%)	46,456 (52.09%)	299,415 (50.56%)
Male	41,473 (48.98%)	77,020 (50.46%)	74,240 (48.06%)	52,326 (47.04%)	41,664 (46.72%)	286,723 (48.42%)
Other	0	3 (0.00%)	2 (0.00%)	4 (0.00%)	0	9 (0.00%)
Unknown	1,030 (1.22%)	1,518 (0.99%)	1,494 (0.97%)	945 (0.85%)	1,066 (1.20%)	6,053 (1.02%)

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Race						
White	46,764 (55.23%)	98,064 (64.25%)	104,527 (67.67%)	74,000 (66.53%)	58,454 (65.54%)	381,809 (64.47%)
Black or African American	11,557 (13.65%)	16,076 (10.53%)	15,711 (10.17%)	11,323 (10.18%)	10,101 (11.33%)	64,768 (10.94%)
Asian	2,787 (3.29%)	3,896 (2.55%)	4,046 (2.62%)	3,966 (3.57%)	2,797 (3.14%)	17,492 (2.95%)
Native Hawaiian or Other Pacific Islander	566 (0.67%)	777 (0.51%)	904 (0.59%)	660 (0.59%)	540 (0.61%)	3,447 (0.58%)
American Indian or Alaska Native	560 (0.66%)	907 (0.59%)	1,043 (0.68%)	785 (0.71%)	586 (0.66%)	3,881 (0.66%)
Other Race	7,887 (9.31%)	11,810 (7.74%)	10,090 (6.53%)	8,416 (7.57%)	6,738 (7.55%)	44,941 (7.59%)
Unknown	14,558 (17.19%)	21,108 (13.83%)	18,140 (11.74%)	12,086 (10.87%)	9,970 (11.18%)	75,862 (12.81%)
Ethnicity						
Hispanic or Latino	12,172 (14.37%)	18,315 (12.00%)	15,264 (9.88%)	12,475 (11.21%)	10,627 (11.92%)	68,853 (11.63%)
Not Hispanic or Latino	57,388 (67.77%)	111,168 (72.83%)	120,821 (78.22%)	87,023 (78.23%)	70,901 (79.50%)	447,301 (75.53%)
Unknown	15,119 (17.85%)	23,155 (15.17%)	18,376 (11.90%)	11,738 (10.55%)	7,658 (8.59%)	76,046 (12.84%)
Virus						
COVID	53,595 (63.29%)	142,142 (93.12%)	132,754 (85.95%)	65,563 (58.94%)	45,646 (51.18%)	439,700 (74.25%)
HMPV	2,578 (3.04%)	82 (0.05%)	2,047 (1.33%)	3,564 (3.20%)	2,497 (2.80%)	10,768 (1.82%)
RSV	5,280 (6.24%)	2,038 (1.34%)	4,118 (2.67%)	7,643 (6.87%)	8,435 (9.46%)	27,514 (4.65%)
Influenza	13,975 (16.50%)	364 (0.24%)	4,271 (2.77%)	15,444 (13.88%)	17,164 (19.25%)	51,218 (8.65%)
Parainfluenza virus	1,346 (1.59%)	1,383 (0.91%)	2,227 (1.44%)	4,099 (3.68%)	3,159 (3.54%)	12,214 (2.06%)
Rhinovirus	7,905 (9.34%)	6,629 (4.34%)	9,044 (5.86%)	14,923 (13.42%)	12,285 (13.77%)	50,786 (8.58%)
Comorbidity						
Asthma	8,076 (9.54%)	12,200 (7.99%)	15,227 (9.86%)	13,529 (12.16%)	12,025 (13.48%)	61,057 (10.31%)
Chronic Lung Disease	5,965 (7.04%)	9,824 (6.44%)	10,853 (7.03%)	8,758 (7.87%)	7,843 (8.79%)	43,243 (7.30%)
Chronic Obstructive Pulmonary Disease	10,779 (12.73%)	16,405 (10.75%)	22,426 (14.52%)	19,313 (17.36%)	16,944 (19.00%)	85,867 (14.50%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019






Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019



Test positivity rate over time

We included 45,736,336 lab results with known results of which 4,378,059 were positive. The test positivity rate is shown in Figure 3.

Figure 3: Weekly test positivity rate since October 2019



COVID-19

Our COVID study population consists of 456,981 hospitalizations of 439,700 unique patients (Table 2).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Table 2: COVID patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	53,595 (100.00%)	142,142 (100.00%)	132,754 (100.00%)	65,563 (100.00%)	45,646 (100.00%)	439,700 (100.00%)
Age Group						
< 6 months	114 (0.21%)	335 (0.24%)	783 (0.59%)	427 (0.65%)	331 (0.73%)	1,990 (0.45%)
6 - <12 months	42 (0.08%)	62 (0.04%)	266 (0.20%)	228 (0.35%)	182 (0.40%)	780 (0.18%)
1 - <2 years	61 (0.11%)	108 (0.08%)	282 (0.21%)	195 (0.30%)	218 (0.48%)	864 (0.20%)
2 - 4 years	104 (0.19%)	113 (0.08%)	421 (0.32%)	266 (0.41%)	226 (0.50%)	1,130 (0.26%)
5 - 17 years	349 (0.65%)	871 (0.61%)	1,313 (0.99%)	576 (0.88%)	484 (1.06%)	3,593 (0.82%)
18 - 49 years	12,655 (23.61%)	32,379 (22.78%)	28,526 (21.49%)	8,357 (12.75%)	4,924 (10.79%)	86,841 (19.75%)
50 - 64 years	13,824 (25.79%)	36,480 (25.66%)	28,267 (21.29%)	9,861 (15.04%)	6,572 (14.40%)	95,004 (21.61%)
65 - 74 years	10,880 (20.30%)	30,298 (21.32%)	27,483 (20.70%)	13,803 (21.05%)	9,584 (21.00%)	92,048 (20.93%)
75 - 84 years	9,588 (17.89%)	26,190 (18.43%)	27,485 (20.70%)	17,943 (27.37%)	13,234 (28.99%)	94,440 (21.48%)
85+ years	5,978 (11.15%)	15,306 (10.77%)	17,928 (13.50%)	13,907 (21.21%)	9,891 (21.67%)	63,010 (14.33%)
Sex						
Female	25,688 (47.93%)	68,799 (48.40%)	67,572 (50.90%)	33,771 (51.51%)	23,155 (50.73%)	218,985 (49.80%)
Male	27,279 (50.90%)	71,910 (50.59%)	63,841 (48.09%)	31,175 (47.55%)	21,848 (47.86%)	216,053 (49.14%)
Other	0	3 (0.00%)	2 (0.00%)	2 (0.00%)	0	7 (0.00%)
Unknown	628 (1.17%)	1,430 (1.01%)	1,339 (1.01%)	615 (0.94%)	643 (1.41%)	4,655 (1.06%)
Race						
White	26,463 (49.38%)	91,748 (64.55%)	90,816 (68.41%)	45,212 (68.96%)	31,174 (68.30%)	285,413 (64.91%)
Black or African American	8,145 (15.20%)	14,561 (10.24%)	13,132 (9.89%)	5,865 (8.95%)	4,510 (9.88%)	46,213 (10.51%)
Asian	1,911 (3.57%)	3,530 (2.48%)	3,210 (2.42%)	2,158 (3.29%)	1,453 (3.18%)	12,262 (2.79%)
Native Hawaiian or Other Pacific Islander	385 (0.72%)	712 (0.50%)	699 (0.53%)	297 (0.45%)	200 (0.44%)	2,293 (0.52%)
American Indian or Alaska Native	337 (0.63%)	837 (0.59%)	866 (0.65%)	385 (0.59%)	283 (0.62%)	2,708 (0.62%)
Other Race	5,831 (10.88%)	10,630 (7.48%)	7,985 (6.01%)	4,035 (6.15%)	2,708 (5.93%)	31,189 (7.09%)
Unknown	10,523 (19.63%)	20,124 (14.16%)	16,046 (12.09%)	7,611 (11.61%)	5,318 (11.65%)	59,622 (13.56%)
Ethnicity						
Hispanic or Latino	9,173 (17.12%)	16,927 (11.91%)	12,306 (9.27%)	5,718 (8.72%)	4,142 (9.07%)	48,266 (10.98%)
Not Hispanic or Latino	33,878 (63.21%)	103,136 (72.56%)	104,190 (78.48%)	52,299 (79.77%)	37,210 (81.52%)	330,713 (75.21%)

Unknown	10,544 (19.67%)	22,079 (15.53%)	16,258 (12.25%)	7,546 (11.51%)	4,294 (9.41%)	60,721 (13.81%)
Comorbidity						
Asthma	3,499 (6.53%)	10,604 (7.46%)	11,971 (9.02%)	6,552 (9.99%)	5,255 (11.51%)	37,881 (8.62%)
Chronic Lung Disease	2,746 (5.12%)	9,029 (6.35%)	9,075 (6.84%)	4,936 (7.53%)	4,011 (8.79%)	29,797 (6.78%)
Chronic Obstructive Pulmonary Disease	4,390 (8.19%)	14,896 (10.48%)	18,864 (14.21%)	11,217 (17.11%)	8,799 (19.28%)	58,166 (13.23%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends.

Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2019





Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season




Test positivity rate over time

We included 25,438,197 COVID lab results with known results of which 2,928,081 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends.

Figure 6: Weekly COVID test positivity rate since October 2019



Figure 7: Weekly COVID test positivity rate by season



Influenza

Our influenza study population consists of 59,425 hospitalizations of 51,218 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	13,975 (100.00%)	364 (100.00%)	4,271 (100.00%)	15,444 (100.00%)	17,164 (100.00%)	51,218 (100.00%)
Age Group						
< 6 months	141 (1.01%)	2 (0.55%)	30 (0.70%)	78 (0.51%)	82 (0.48%)	333 (0.65%)
6 - <12 months	90 (0.64%)	0	16 (0.37%)	68 (0.44%)	47 (0.27%)	221 (0.43%)
1 - <2 years	130 (0.93%)	1 (0.27%)	31 (0.73%)	112 (0.73%)	82 (0.48%)	356 (0.70%)
2 - 4 years	180 (1.29%)	2 (0.55%)	56 (1.31%)	239 (1.55%)	194 (1.13%)	671 (1.31%)
5 - 17 years	340 (2.43%)	3 (0.82%)	169 (3.96%)	561 (3.63%)	492 (2.87%)	1,565 (3.06%)
18 - 49 years	2,798 (20.02%)	123 (33.79%)	950 (22.24%)	3,012 (19.50%)	3,472 (20.23%)	10,355 (20.22%)
50 - 64 years	3,447 (24.67%)	83 (22.80%)	774 (18.12%)	3,193 (20.67%)	3,769 (21.96%)	11,266 (22.00%)
65 - 74 years	2,901 (20.76%)	59 (16.21%)	837 (19.60%)	3,264 (21.13%)	3,677 (21.42%)	10,738 (20.97%)
75 - 84 years	2,414 (17.27%)	63 (17.31%)	838 (19.62%)	3,104 (20.10%)	3,418 (19.91%)	9,837 (19.21%)
85+ years	1,534 (10.98%)	28 (7.69%)	570 (13.35%)	1,813 (11.74%)	1,931 (11.25%)	5,876 (11.47%)

Sex						
Female	7,607 (54.43%)	226 (62.09%)	2,425 (56.78%)	8,544 (55.32%)	9,331 (54.36%)	28,133 (54.93%)
Male	6,181 (44.23%)	133 (36.54%)	1,807 (42.31%)	6,785 (43.93%)	7,677 (44.73%)	22,583 (44.09%)
Other	0	0	0	2 (0.01%)	0	2 (0.00%)
Unknown	187 (1.34%)	5 (1.37%)	39 (0.91%)	113 (0.73%)	156 (0.91%)	500 (0.98%)
Race						
White	9,034 (64.64%)	244 (67.03%)	2,880 (67.43%)	10,260 (66.43%)	11,031 (64.27%)	33,449 (65.31%)
Black or African American	1,720 (12.31%)	47 (12.91%)	541 (12.67%)	1,956 (12.67%)	2,462 (14.34%)	6,726 (13.13%)
Asian	360 (2.58%)	4 (1.10%)	91 (2.13%)	424 (2.75%)	460 (2.68%)	1,339 (2.61%)
Native Hawaiian or Other Pacific Islander	68 (0.49%)	1 (0.27%)	38 (0.89%)	116 (0.75%)	135 (0.79%)	358 (0.70%)
American Indian or Alaska Native	90 (0.64%)	3 (0.82%)	40 (0.94%)	142 (0.92%)	125 (0.73%)	400 (0.78%)
Other Race	755 (5.40%)	14 (3.85%)	241 (5.64%)	1,081 (7.00%)	1,258 (7.33%)	3,349 (6.54%)
Unknown	1,948 (13.94%)	51 (14.01%)	440 (10.30%)	1,465 (9.49%)	1,693 (9.86%)	5,597 (10.93%)
Ethnicity						
Hispanic or Latino	1,248 (8.93%)	29 (7.97%)	431 (10.09%)	1,870 (12.11%)	2,216 (12.91%)	5,794 (11.31%)
Not Hispanic or Latino	10,543 (75.44%)	275 (75.55%)	3,378 (79.09%)	12,225 (79.16%)	13,697 (79.80%)	40,118 (78.33%)
Unknown	2,184 (15.63%)	60 (16.48%)	462 (10.82%)	1,349 (8.73%)	1,251 (7.29%)	5,306 (10.36%)
Comorbidity						
Asthma	1,908 (13.65%)	33 (9.07%)	655 (15.34%)	2,320 (15.02%)	2,634 (15.35%)	7,550 (14.74%)
Chronic Lung Disease	1,314 (9.40%)	26 (7.14%)	398 (9.32%)	1,401 (9.07%)	1,606 (9.36%)	4,745 (9.26%)
Chronic Obstructive Pulmonary Disease	2,849 (20.39%)	53 (14.56%)	907 (21.24%)	3,213 (20.80%)	3,495 (20.36%)	10,517 (20.53%)


Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends.

Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2019



Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season




Test positivity rate over time

We included 11,158,538 influenza lab results with known results of which 879,003 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Weekly influenza test positivity rate since October 2019



Figure 11: Weekly influenza test positivity rate by season



Human metapneumovirus (HMPV)

Our HMPV study population consists of 15,048 hospitalizations of 10,768 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	2,578 (100.00%)	82 (100.00%)	2,047 (100.00%)	3,564 (100.00%)	2,497 (100.00%)	10,768 (100.00%)
Age Group						
< 6 months	60 (2.33%)	2 (2.44%)	72 (3.52%)	145 (4.07%)	69 (2.76%)	348 (3.23%)
6 - <12 months	62 (2.40%)	1 (1.22%)	88 (4.30%)	105 (2.95%)	76 (3.04%)	332 (3.08%)
1 - <2 years	73 (2.83%)	8 (9.76%)	126 (6.16%)	145 (4.07%)	71 (2.84%)	423 (3.93%)
2 - 4 years	79 (3.06%)	10 (12.20%)	179 (8.74%)	246 (6.90%)	111 (4.45%)	625 (5.80%)
5 - 17 years	61 (2.37%)	0	91 (4.45%)	135 (3.79%)	88 (3.52%)	375 (3.48%)
18 - 49 years	272 (10.55%)	12 (14.63%)	226 (11.04%)	368 (10.33%)	301 (12.05%)	1,179 (10.95%)
50 - 64 years	523 (20.29%)	19 (23.17%)	341 (16.66%)	584 (16.39%)	427 (17.10%)	1,894 (17.59%)
65 - 74 years	514 (19.94%)	10 (12.20%)	349 (17.05%)	679 (19.05%)	494 (19.78%)	2,046 (19.00%)
75 - 84 years	548 (21.26%)	14 (17.07%)	359 (17.54%)	705 (19.78%)	513 (20.54%)	2,139 (19.86%)
85+ years	386 (14.97%)	6 (7.32%)	216 (10.55%)	452 (12.68%)	347 (13.90%)	1,407 (13.07%)
Sex						
Female	1,468 (56.94%)	38 (46.34%)	1,154 (56.38%)	2,028 (56.90%)	1,516 (60.71%)	6,204 (57.62%)
Male	1,080 (41.89%)	43 (52.44%)	879 (42.94%)	1,516 (42.54%)	958 (38.37%)	4,476 (41.57%)
Unknown	30 (1.16%)	1 (1.22%)	14 (0.68%)	20 (0.56%)	23 (0.92%)	88 (0.82%)
Race						
White	1,930 (74.86%)	56 (68.29%)	1,518 (74.16%)	2,540 (71.27%)	1,676 (67.12%)	7,720 (71.69%)
Black or African American	188 (7.29%)	8 (9.76%)	169 (8.26%)	278 (7.80%)	221 (8.85%)	864 (8.02%)
Asian	48 (1.86%)	0	42 (2.05%)	104 (2.92%)	70 (2.80%)	264 (2.45%)
Native Hawaiian or Other Pacific Islander	13 (0.50%)	0	13 (0.64%)	16 (0.45%)	9 (0.36%)	51 (0.47%)
American Indian or Alaska Native	17 (0.66%)	1 (1.22%)	10 (0.49%)	33 (0.93%)	18 (0.72%)	79 (0.73%)
Other Race	108 (4.19%)	6 (7.32%)	120 (5.86%)	318 (8.92%)	261 (10.45%)	813 (7.55%)
Unknown	274 (10.63%)	11 (13.41%)	175 (8.55%)	275 (7.72%)	242 (9.69%)	977 (9.07%)
Ethnicity						
Hispanic or Latino	196 (7.60%)	14 (17.07%)	248 (12.12%)	569 (15.97%)	424 (16.98%)	1,451 (13.48%)
Not Hispanic or Latino	2,049 (79.48%)	61 (74.39%)	1,620 (79.14%)	2,720 (76.32%)	1,910 (76.49%)	8,360 (77.64%)
Unknown	333 (12.92%)	7 (8.54%)	179 (8.74%)	275 (7.72%)	163 (6.53%)	957 (8.89%)
Comorbidity						
Asthma	412 (15.98%)	9 (10.98%)	305 (14.90%)	570 (15.99%)	416 (16.66%)	1,712 (15.90%)
Chronic Lung Disease	348 (13.50%)	7 (8.54%)	254 (12.41%)	397 (11.14%)	266 (10.65%)	1,272 (11.81%)
Chronic Obstructive Pulmonary Disease	614 (23.82%)	14 (17.07%)	424 (20.71%)	727 (20.40%)	470 (18.82%)	2,249 (20.89%)

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends.

Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2019





Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season




Test positivity rate over time

We included 1,440,685 HMPV lab results with known results of which 41,096 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends.

Figure 14: Weekly HMPV test positivity rate since October 2019



Figure 15: Weekly HMPV test positivity rate by season



Parainfluenza virus

Our parainfluenza virus study population consists of 14,842 hospitalizations of 12,214 unique patients (Table 5).

Table 5: Parainfluenza virus patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	1,346 (100.00%)	1,383 (100.00%)	2,227 (100.00%)	4,099 (100.00%)	3,159 (100.00%)	12,214 (100.00%)
Age Group						
< 6 months	77 (5.72%)	94 (6.80%)	128 (5.75%)	213 (5.20%)	123 (3.89%)	635 (5.20%)
6 - <12 months	41 (3.05%)	70 (5.06%)	94 (4.22%)	148 (3.61%)	68 (2.15%)	421 (3.45%)
1 - <2 years	60 (4.46%)	102 (7.38%)	115 (5.16%)	173 (4.22%)	118 (3.74%)	568 (4.65%)
2 - 4 years	79 (5.87%)	110 (7.95%)	194 (8.71%)	267 (6.51%)	150 (4.75%)	800 (6.55%)
5 - 17 years	64 (4.75%)	84 (6.07%)	114 (5.12%)	211 (5.15%)	123 (3.89%)	596 (4.88%)
18 - 49 years	132 (9.81%)	183 (13.23%)	264 (11.85%)	464 (11.32%)	332 (10.51%)	1,375 (11.26%)
50 - 64 years	243 (18.05%)	230 (16.63%)	380 (17.06%)	676 (16.49%)	559 (17.70%)	2,088 (17.10%)
65 - 74 years	227 (16.86%)	220 (15.91%)	386 (17.33%)	681 (16.61%)	587 (18.58%)	2,101 (17.20%)
75 - 84 years	236 (17.53%)	185 (13.38%)	318 (14.28%)	737 (17.98%)	670 (21.21%)	2,146 (17.57%)
85+ years	187 (13.89%)	105 (7.59%)	234 (10.51%)	529 (12.91%)	429 (13.58%)	1,484 (12.15%)
Sex						
Female	725 (53.86%)	716 (51.77%)	1,205 (54.11%)	2,219 (54.14%)	1,699 (53.78%)	6,564 (53.74%)
Male	599 (44.50%)	653 (47.22%)	1,008 (45.26%)	1,850 (45.13%)	1,423 (45.05%)	5,533 (45.30%)
Unknown	22 (1.63%)	14 (1.01%)	14 (0.63%)	30 (0.73%)	37 (1.17%)	117 (0.96%)
Race						
White	894 (66.42%)	868 (62.76%)	1,396 (62.69%)	2,564 (62.55%)	1,962 (62.11%)	7,684 (62.91%)
Black or African American	121 (8.99%)	178 (12.87%)	233 (10.46%)	432 (10.54%)	359 (11.36%)	1,323 (10.83%)
Asian	53 (3.94%)	40 (2.89%)	95 (4.27%)	192 (4.68%)	100 (3.17%)	480 (3.93%)
Native Hawaiian or Other Pacific Islander	15 (1.11%)	4 (0.29%)	12 (0.54%)	20 (0.49%)	28 (0.89%)	79 (0.65%)
American Indian or Alaska Native	8 (0.59%)	12 (0.87%)	21 (0.94%)	41 (1.00%)	23 (0.73%)	105 (0.86%)
Other Race	90 (6.69%)	146 (10.56%)	227 (10.19%)	449 (10.95%)	335 (10.60%)	1,247 (10.21%)

Unknown	165 (12.26%)	135 (9.76%)	243 (10.91%)	401 (9.78%)	352 (11.14%)	1,296 (10.61%)
Ethnicity						
Hispanic or Latino	112 (8.32%)	162 (11.71%)	295 (13.25%)	602 (14.69%)	488 (15.45%)	1,659 (13.58%)
Not Hispanic or Latino	1,042 (77.41%)	1,062 (76.79%)	1,664 (74.72%)	3,084 (75.24%)	2,414 (76.42%)	9,266 (75.86%)
Unknown	192 (14.26%)	159 (11.50%)	268 (12.03%)	413 (10.08%)	257 (8.14%)	1,289 (10.55%)
Comorbidity						
Asthma	213 (15.82%)	203 (14.68%)	345 (15.49%)	641 (15.64%)	506 (16.02%)	1,908 (15.62%)
Chronic Lung Disease	181 (13.45%)	116 (8.39%)	236 (10.60%)	391 (9.54%)	351 (11.11%)	1,275 (10.44%)
Chronic Obstructive Pulmonary Disease	303 (22.51%)	265 (19.16%)	473 (21.24%)	826 (20.15%)	714 (22.60%)	2,581 (21.13%)


Hospitalization rate over time

The rate of parainfluenza virus-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends.

Figure 16: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 17: Rate of weekly parainfluenza virus-associated hospitalizations compared to all hospital admissions by season




Test positivity rate over time

We included 1,539,148 parainfluenza virus lab results with known results of which 59,776 were positive. The parainfluenza virus test positivity rate is shown in Figure 18. Figure 19 shows yearly trends.

Figure 18: Weekly parainfluenza virus test positivity rate since October 2019



Figure 19: Weekly parainfluenza virus test positivity rate by season



Respiratory syncytial virus (RSV)

Our RSV study population consists of 34,850 hospitalizations of 27,514 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	5,280 (100.00%)	2,038 (100.00%)	4,118 (100.00%)	7,643 (100.00%)	8,435 (100.00%)	27,514 (100.00%)
Age Group						
< 6 months	954 (18.07%)	576 (28.26%)	795 (19.31%)	1,535 (20.08%)	1,120 (13.28%)	4,980 (18.10%)
6 - <12 months	359 (6.80%)	163 (8.00%)	291 (7.07%)	538 (7.04%)	454 (5.38%)	1,805 (6.56%)
1 - <2 years	332 (6.29%)	197 (9.67%)	354 (8.60%)	597 (7.81%)	460 (5.45%)	1,940 (7.05%)
2 - 4 years	330 (6.25%)	168 (8.24%)	341 (8.28%)	722 (9.45%)	400 (4.74%)	1,961 (7.13%)
5 - 17 years	94 (1.78%)	43 (2.11%)	123 (2.99%)	255 (3.34%)	204 (2.42%)	719 (2.61%)
18 - 49 years	271 (5.13%)	165 (8.10%)	351 (8.52%)	531 (6.95%)	692 (8.20%)	2,010 (7.31%)
50 - 64 years	632 (11.97%)	228 (11.19%)	475 (11.53%)	785 (10.27%)	1,158 (13.73%)	3,278 (11.91%)
65 - 74 years	749 (14.19%)	209 (10.26%)	510 (12.38%)	973 (12.73%)	1,321 (15.66%)	3,762 (13.67%)
75 - 84 years	887 (16.80%)	174 (8.54%)	526 (12.77%)	996 (13.03%)	1,480 (17.55%)	4,063 (14.77%)
85+ years	672 (12.73%)	115 (5.64%)	352 (8.55%)	711 (9.30%)	1,146 (13.59%)	2,996 (10.89%)

Sex						
Female	2,830 (53.60%)	1,081 (53.04%)	2,111 (51.26%)	4,029 (52.71%)	4,623 (54.81%)	14,674 (53.33%)
Male	2,397 (45.40%)	947 (46.47%)	1,985 (48.20%)	3,562 (46.60%)	3,728 (44.20%)	12,619 (45.86%)
Unknown	53 (1.00%)	10 (0.49%)	22 (0.53%)	52 (0.68%)	84 (1.00%)	221 (0.80%)
Race						
White	3,457 (65.47%)	1,227 (60.21%)	2,666 (64.74%)	4,747 (62.11%)	5,458 (64.71%)	17,555 (63.80%)
Black or African American	488 (9.24%)	336 (16.49%)	436 (10.59%)	779 (10.19%)	887 (10.52%)	2,926 (10.63%)
Asian	153 (2.90%)	55 (2.70%)	190 (4.61%)	431 (5.64%)	341 (4.04%)	1,170 (4.25%)
Native Hawaiian or Other Pacific Islander	30 (0.57%)	17 (0.83%)	74 (1.80%)	142 (1.86%)	103 (1.22%)	366 (1.33%)
American Indian or Alaska Native	37 (0.70%)	15 (0.74%)	40 (0.97%)	62 (0.81%)	67 (0.79%)	221 (0.80%)
Other Race	435 (8.24%)	195 (9.57%)	339 (8.23%)	714 (9.34%)	659 (7.81%)	2,342 (8.51%)
Unknown	680 (12.88%)	193 (9.47%)	373 (9.06%)	768 (10.05%)	920 (10.91%)	2,934 (10.66%)
Ethnicity						
Hispanic or Latino	617 (11.69%)	271 (13.30%)	571 (13.87%)	1,210 (15.83%)	1,150 (13.63%)	3,819 (13.88%)
Not Hispanic or Latino	3,901 (73.88%)	1,561 (76.59%)	3,168 (76.93%)	5,719 (74.83%)	6,555 (77.71%)	20,904 (75.98%)
Unknown	762 (14.43%)	206 (10.11%)	379 (9.20%)	714 (9.34%)	730 (8.65%)	2,791 (10.14%)
Comorbidity						
Asthma	662 (12.54%)	214 (10.50%)	524 (12.72%)	968 (12.67%)	1,171 (13.88%)	3,539 (12.86%)
Chronic Lung Disease	460 (8.71%)	123 (6.04%)	264 (6.41%)	538 (7.04%)	709 (8.41%)	2,094 (7.61%)
Chronic Obstructive Pulmonary Disease	1,044 (19.77%)	240 (11.78%)	642 (15.59%)	1,199 (15.69%)	1,603 (19.00%)	4,728 (17.18%)


Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends.

Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2019



Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 4,685,800 RSV lab results with known results of which 232,834 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends.

Figure 22: Weekly RSV test positivity rate since October 2019





Figure 23: Weekly RSV test positivity rate by season



Rhinovirus

Our rhinovirus study population consists of 61,675 hospitalizations of 50,786 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	7,905 (100.00%)	6,629 (100.00%)	9,044 (100.00%)	14,923 (100.00%)	12,285 (100.00%)	50,786 (100.00%)
Age Group						
< 6 months	491 (6.21%)	498 (7.51%)	748 (8.27%)	875 (5.86%)	609 (4.96%)	3,221 (6.34%)
6 - <12 months	256 (3.24%)	290 (4.37%)	397 (4.39%)	454 (3.04%)	351 (2.86%)	1,748 (3.44%)
1 - <2 years	377 (4.77%)	563 (8.49%)	784 (8.67%)	872 (5.84%)	607 (4.94%)	3,203 (6.31%)
2 - 4 years	511 (6.46%)	640 (9.65%)	1,226 (13.56%)	1,387 (9.29%)	874 (7.11%)	4,638 (9.13%)
5 - 17 years	522 (6.60%)	779 (11.75%)	1,174 (12.98%)	1,732 (11.61%)	1,280 (10.42%)	5,487 (10.80%)
18 - 49 years	1,245 (15.75%)	1,275 (19.23%)	1,232 (13.62%)	2,356 (15.79%)	2,090 (17.01%)	8,198 (16.14%)
50 - 64 years	1,388 (17.56%)	904 (13.64%)	1,078 (11.92%)	2,106 (14.11%)	1,867 (15.20%)	7,343 (14.46%)
65 - 74 years	1,218 (15.41%)	735 (11.09%)	1,049 (11.60%)	2,089 (14.00%)	1,856 (15.11%)	6,947 (13.68%)
75 - 84 years	1,095 (13.85%)	573 (8.64%)	812 (8.98%)	1,831 (12.27%)	1,634 (13.30%)	5,945 (11.71%)
85+ years	802 (10.15%)	372 (5.61%)	544 (6.02%)	1,221 (8.18%)	1,117 (9.09%)	4,056 (7.99%)
Sex						
Female	3,858 (48.80%)	3,237 (48.83%)	4,258 (47.08%)	7,370 (49.39%)	6,132 (49.91%)	24,855 (48.94%)
Male	3,937 (49.80%)	3,334 (50.29%)	4,720 (52.19%)	7,438 (49.84%)	6,030 (49.08%)	25,459 (50.13%)
Unknown	110 (1.39%)	58 (0.87%)	66 (0.73%)	115 (0.77%)	123 (1.00%)	472 (0.93%)
Race						
White	4,986 (63.07%)	3,921 (59.15%)	5,251 (58.06%)	8,677 (58.15%)	7,153 (58.23%)	29,988 (59.05%)
Black or African American	895 (11.32%)	946 (14.27%)	1,200 (13.27%)	2,013 (13.49%)	1,662 (13.53%)	6,716 (13.22%)
Asian	262 (3.31%)	267 (4.03%)	418 (4.62%)	657 (4.40%)	373 (3.04%)	1,977 (3.89%)
Native Hawaiian or Other Pacific Islander	55 (0.70%)	43 (0.65%)	68 (0.75%)	69 (0.46%)	65 (0.53%)	300 (0.59%)
American Indian or Alaska Native	71 (0.90%)	39 (0.59%)	66 (0.73%)	122 (0.82%)	70 (0.57%)	368 (0.72%)
Other Race	668 (8.45%)	819 (12.35%)	1,178 (13.03%)	1,819 (12.19%)	1,517 (12.35%)	6,001 (11.82%)
Unknown	968 (12.25%)	594 (8.96%)	863 (9.54%)	1,566 (10.49%)	1,445 (11.76%)	5,436 (10.70%)
Ethnicity						
Hispanic or Latino	826 (10.45%)	912 (13.76%)	1,413 (15.62%)	2,506 (16.79%)	2,207 (17.96%)	7,864 (15.48%)
Not Hispanic or Latino	5,975 (75.59%)	5,073 (76.53%)	6,801 (75.20%)	10,976 (73.55%)	9,115 (74.20%)	37,940 (74.71%)
Unknown	1,104 (13.97%)	644 (9.71%)	830 (9.18%)	1,441 (9.66%)	963 (7.84%)	4,982 (9.81%)
Comorbidity						
Asthma	1,382 (17.48%)	1,137 (17.15%)	1,427 (15.78%)	2,478 (16.61%)	2,043 (16.63%)	8,467 (16.67%)
Chronic Lung Disease	916 (11.59%)	523 (7.89%)	626 (6.92%)	1,095 (7.34%)	900 (7.33%)	4,060 (7.99%)
Chronic Obstructive Pulmonary Disease	1,579 (19.97%)	937 (14.13%)	1,116 (12.34%)	2,131 (14.28%)	1,863 (15.16%)	7,626 (15.02%)


Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends.

Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2019



Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season




Test positivity rate over time

We included 1,473,968 rhinovirus lab results with known results of which 237,269 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends.

Figure 26: Weekly rhinovirus test positivity rate since October 2019



Figure 27: Weekly rhinovirus test positivity rate by season



Infants and children (age 0-4)

Our infants and children study population consists of 44,011 hospitalizations of 33,993 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.


	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	5,003 (100.00%)	4,115 (100.00%)	7,817 (100.00%)	10,035 (100.00%)	7,023 (100.00%)	33,993 (100.00%)
Age Group						
< 6 months	1,837 (36.72%)	1,507 (36.62%)	2,556 (32.70%)	3,273 (32.62%)	2,334 (33.23%)	11,507 (33.85%)
6 - <12 months	850 (16.99%)	586 (14.24%)	1,152 (14.74%)	1,541 (15.36%)	1,178 (16.77%)	5,307 (15.61%)
1 - <2 years	1,033 (20.65%)	979 (23.79%)	1,692 (21.65%)	2,094 (20.87%)	1,556 (22.16%)	7,354 (21.63%)
2 - 4 years	1,283 (25.64%)	1,043 (25.35%)	2,417 (30.92%)	3,127 (31.16%)	1,955 (27.84%)	9,825 (28.90%)
Sex						
Female	2,176 (43.49%)	1,733 (42.11%)	3,244 (41.50%)	4,363 (43.48%)	3,065 (43.64%)	14,581 (42.89%)
Male	2,825 (56.47%)	2,381 (57.86%)	4,560 (58.33%)	5,658 (56.38%)	3,943 (56.14%)	19,367 (56.97%)
Unknown	2 (0.04%)	1 (0.02%)	13 (0.17%)	14 (0.14%)	15 (0.21%)	45 (0.13%)
Race						
White	2,482 (49.61%)	2,082 (50.60%)	3,909 (50.01%)	4,719 (47.03%)	3,272 (46.59%)	16,464 (48.43%)
Black or African American	783 (15.65%)	723 (17.57%)	1,167 (14.93%)	1,432 (14.27%)	992 (14.13%)	5,097 (14.99%)
Asian	301 (6.02%)	191 (4.64%)	509 (6.51%)	797 (7.94%)	448 (6.38%)	2,246 (6.61%)
Native Hawaiian or Other Pacific Islander	89 (1.78%)	66 (1.60%)	173 (2.21%)	211 (2.10%)	171 (2.43%)	710 (2.09%)
American Indian or Alaska Native	54 (1.08%)	30 (0.73%)	69 (0.88%)	117 (1.17%)	54 (0.77%)	324 (0.95%)
Other Race	835 (16.69%)	721 (17.52%)	1,288 (16.48%)	1,696 (16.90%)	1,163 (16.56%)	5,703 (16.78%)
Unknown	459 (9.17%)	302 (7.34%)	702 (8.98%)	1,063 (10.59%)	923 (13.14%)	3,449 (10.15%)

Ethnicity						
Hispanic or Latino	1,120 (22.39%)	819 (19.90%)	1,690 (21.62%)	2,605 (25.96%)	1,770 (25.20%)	8,004 (23.55%)
Not Hispanic or Latino	3,374 (67.44%)	2,976 (72.32%)	5,521 (70.63%)	6,571 (65.48%)	4,637 (66.03%)	23,079 (67.89%)
Unknown	509 (10.17%)	320 (7.78%)	606 (7.75%)	859 (8.56%)	616 (8.77%)	2,910 (8.56%)
Virus						
COVID	321 (6.42%)	618 (15.02%)	1,752 (22.41%)	1,116 (11.12%)	957 (13.63%)	4,764 (14.01%)
HMPV	274 (5.48%)	21 (0.51%)	465 (5.95%)	641 (6.39%)	327 (4.66%)	1,728 (5.08%)
RSV	1,975 (39.48%)	1,104 (26.83%)	1,781 (22.78%)	3,392 (33.80%)	2,434 (34.66%)	10,686 (31.44%)
influenza	541 (10.81%)	5 (0.12%)	133 (1.70%)	497 (4.95%)	405 (5.77%)	1,581 (4.65%)
parainfluenza virus	257 (5.14%)	376 (9.14%)	531 (6.79%)	801 (7.98%)	459 (6.54%)	2,424 (7.13%)
rhinovirus	1,635 (32.68%)	1,991 (48.38%)	3,155 (40.36%)	3,588 (35.75%)	2,441 (34.76%)	12,810 (37.68%)
Comorbidity						
Asthma	363 (7.26%)	292 (7.10%)	467 (5.97%)	656 (6.54%)	467 (6.65%)	2,245 (6.60%)
Chronic Lung Disease	63 (1.26%)	26 (0.63%)	45 (0.58%)	67 (0.67%)	51 (0.73%)	252 (0.74%)
Chronic Obstructive Pulmonary Disease	4 (0.08%)	3 (0.07%)	10 (0.13%)	13 (0.13%)	16 (0.23%)	46 (0.14%)

Hospitalization rate over time


The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses.

Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).


Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for infants and children under five



Test positivity rate over time

We included 4,850,529 lab results with known results of infants and children under age five. Of those tests, 563,330 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30.

Figure 30: Weekly test positivity rate since October 2019 for infants and children under five



Older adults (age 65 and over)

Our older adults study population consists of 338,698 hospitalizations of 315,041 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2019/2020	2020/2021	2021/2022	2022/2023	2023/2024	Overall
N	40,816 (100.00%)	74,662 (100.00%)	80,796 (100.00%)	65,438 (100.00%)	53,329 (100.00%)	315,041 (100.00%)
Age Group						
65 - 74 years	16,489 (40.40%)	31,531 (42.23%)	30,614 (37.89%)	21,489 (32.84%)	17,519 (32.85%)	117,642 (37.34%)
75 - 84 years	14,768 (36.18%)	27,199 (36.43%)	30,338 (37.55%)	25,316 (38.69%)	20,949 (39.28%)	118,570 (37.64%)
85+ years	9,559 (23.42%)	15,932 (21.34%)	19,844 (24.56%)	18,633 (28.47%)	14,861 (27.87%)	78,829 (25.02%)

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .

Sex						
Female	20,692 (50.70%)	36,425 (48.79%)	40,496 (50.12%)	34,395 (52.56%)	27,966 (52.44%)	159,974 (50.78%)
Male	19,855 (48.65%)	37,882 (50.74%)	39,882 (49.36%)	30,653 (46.84%)	24,834 (46.57%)	153,106 (48.60%)
Unknown	269 (0.66%)	355 (0.48%)	418 (0.52%)	390 (0.60%)	529 (0.99%)	1,961 (0.62%)
Race						
White	25,839 (63.31%)	53,949 (72.26%)	60,851 (75.31%)	48,740 (74.48%)	38,896 (72.94%)	228,275 (72.46%)
Black or African American	4,013 (9.83%)	5,059 (6.78%)	5,370 (6.65%)	4,295 (6.56%)	4,063 (7.62%)	22,800 (7.24%)
Asian	1,017 (2.49%)	1,425 (1.91%)	1,666 (2.06%)	1,882 (2.88%)	1,451 (2.72%)	7,441 (2.36%)
Native Hawaiian or Other Pacific Islander	80 (0.20%)	143 (0.19%)	178 (0.22%)	173 (0.26%)	127 (0.24%)	701 (0.22%)
American Indian or Alaska Native	127 (0.31%)	220 (0.29%)	306 (0.38%)	302 (0.46%)	248 (0.47%)	1,203 (0.38%)
Other Race	1,965 (4.81%)	2,970 (3.98%)	2,764 (3.42%)	2,920 (4.46%)	2,639 (4.95%)	13,258 (4.21%)
Unknown	7,775 (19.05%)	10,896 (14.59%)	9,661 (11.96%)	7,126 (10.89%)	5,905 (11.07%)	41,363 (13.13%)
Ethnicity						
Hispanic or Latino	2,595 (6.36%)	4,152 (5.56%)	3,810 (4.72%)	3,910 (5.98%)	3,818 (7.16%)	18,285 (5.80%)
Not Hispanic or Latino	29,377 (71.97%)	57,170 (76.57%)	65,864 (81.52%)	53,817 (82.24%)	44,518 (83.48%)	250,746 (79.59%)
Unknown	8,844 (21.67%)	13,340 (17.87%)	11,122 (13.77%)	7,711 (11.78%)	4,993 (9.36%)	46,010 (14.60%)
Virus						
COVID	26,446 (64.79%)	71,794 (96.16%)	72,896 (90.22%)	45,653 (69.77%)	32,709 (61.33%)	249,498 (79.20%)
HMPV	1,448 (3.55%)	30 (0.04%)	924 (1.14%)	1,836 (2.81%)	1,354 (2.54%)	5,592 (1.78%)
RSV	2,308 (5.65%)	498 (0.67%)	1,388 (1.72%)	2,680 (4.10%)	3,947 (7.40%)	10,821 (3.43%)
influenza	6,849 (16.78%)	150 (0.20%)	2,245 (2.78%)	8,181 (12.50%)	9,026 (16.93%)	26,451 (8.40%)
parainfluenza virus	650 (1.59%)	510 (0.68%)	938 (1.16%)	1,947 (2.98%)	1,686 (3.16%)	5,731 (1.82%)
rhinovirus	3,115 (7.63%)	1,680 (2.25%)	2,405 (2.98%)	5,141 (7.86%)	4,607 (8.64%)	16,948 (5.38%)
Comorbidity						
Asthma	3,494 (8.56%)	5,389 (7.22%)	6,965 (8.62%)	6,804 (10.40%)	6,099 (11.44%)	28,751 (9.13%)
Chronic Lung Disease	3,280 (8.04%)	5,472 (7.33%)	6,531 (8.08%)	5,947 (9.09%)	5,319 (9.97%)	26,549 (8.43%)
Chronic Obstructive Pulmonary Disease	7,653 (18.75%)	12,234 (16.39%)	16,554 (20.49%)	14,858 (22.71%)	13,075 (24.52%)	64,374 (20.43%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older






Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



Test positivity rate over time

We included 13,340,098 lab results with known results of adults aged 65 and over. Of those tests, 940,503 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2019 for adults 65 years or older



Discussion and conclusion

For the overall population, the rate of hospitalizations associated with respiratory viruses remained unchanged in August 2024 compared to July 2024. The slight

decrease in COVID-associated hospitalizations (-2.9%) and the significant drop in influenza-associated hospitalizations (-57.4%) contributed to this stability. In the last week of August, respiratory virus-associated hospitalizations accounted for 2.5% of all hospitalizations.

For August, test positivity for COVID is high (20.9%) but falling (-5.3%). Test positivity for rhinovirus is high (15.1%) and rising through August (+63.9%). For other viruses, test positivity is relatively low with parainfluenza having the next highest test positivity at 1.4%. No other viruses have a rising test positivity.

In the population aged 0-4 years, respiratory virus-associated hospitalizations increased significantly by 40.6% throughout August 2024. This rise was primarily driven by increases in rhinovirus-associated hospitalizations, which rose by 80.9%. In the last week of August, 2.4% of all hospitalizations in this age group were associated with a respiratory virus, with rhinovirus being the largest contributor at 1.8%.

Among older adults (age 65 and over), there was a slight decrease of 4.7% in hospitalizations associated with respiratory viruses in August 2024 compared to July 2024. COVID-associated hospitalizations remained stable, while influenza-associated hospitalizations saw a significant decline of 62.9%. In the last week of August, respiratory virus-associated hospitalizations accounted for 3.4% of all hospitalizations in this age group, with rhinovirus remaining a consistent contributor.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed September 09, 2024. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

- Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. *The Journal of Pediatrics*, 137(6), 865-870. <https://doi.org/10.1067/mpd.2000.110531>
- Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. <https://www.cdc.gov/flu/about/burden/past-seasons.html>
- Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. <https://www.cdc.gov/surveillance/nrevss/index.html>
- Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. <https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm>
- Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. <https://www.cdc.gov/rsv/research/rsv-net/dashboard.html>
- Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., ... Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. *Pediatrics*, 134(2), e620-e638. <https://doi.org/10.1542/peds.2014-1666>
- Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahan, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), *Open Forum Infectious Diseases*, Volume 6, Issue 7, July 2019, ofz225, <https://doi.org/10.1093/ofid/ofz225>
- Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High

Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. *Clinical Infectious Diseases*, 57(8), 1069–1077. <https://doi.org/10.1093/cid/cit471>

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. *Open Forum Infectious Diseases*, 4(1), ofw270. <https://doi.org/10.1093/ofid/ofw270>

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., ... Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. *The Lancet*, 390(10098), 946–958. [https://doi.org/10.1016/S0140-6736\(17\)30938-8](https://doi.org/10.1016/S0140-6736(17)30938-8)

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. *Vaccine*. 2023 Apr 6;41(15):2447-2455. <https://doi.org/10.1016/j.vaccine.2023.02.038>. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. *Clin Infect Dis*. 2018 May 2;66(10):1511-1518. <https://doi.org/10.1093/cid/cix1060>. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. <https://resources.truveta.com/patient-privacy>